Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients

Abstract Objective Inhibition of fibroblast growth factor (FGF) 19‐FGF Receptor 4 (FGFR4) signaling demonstrates potent anticancer activity. EVER4010001 is a highly selective FGFR4 inhibitor and pembrolizumab is approved for the treatment of several solid tumors. This study determined the maximum to...

Full description

Bibliographic Details
Main Authors: Jianming Xu, Jiuwei Cui, Haiping Jiang, Yan Zeng, Xiuyu Cong
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
FGF19
FGFR4
pembrolizumab
Phase 1
solid tumor
Online Access:https://doi.org/10.1002/cam4.5532

Internet

https://doi.org/10.1002/cam4.5532

Similar Items